The PAWS Pet Company, Inc. Executes Agreement to

New Post Public Reply Private Reply Replies (1) Message Board
MicroCapStocksRock PoemStone #17751

The PAWS Pet Company, Inc. Executes Agreement to Acquire MESA Pharmacy, Inc. Orders expected to exceed $25 Million in 2014

Paws Pet Company, Inc. (QB) (USOTC AWS)
Intraday Stock Chart

Today : Tuesday 29 October 2013

Click Here for more Paws Pet Company, Inc. (QB) Charts.

The PAWS Pet Company, Inc. (OTCQB AWS), announced it has executed an agreement to acquire MESA Pharmacy, Inc. as part of its new strategy to become a dominant player in the delivery of compounded pharmaceutical products to consumers.

PALO ALTO, CA Oct. 29, 2013 /PRNewswire/ - The PAWS Pet Company, Inc. (OTCQB AWS) has executed an agreement to acquire MESA Pharmacy, Inc. (MESA) from its parent, Pharmacy Development Corp. in exchange for preferred  stock . PAWS will be filing a report on Form 8-K within the next few days. Previously, the Company had announced that it and PDC had determined to enter into a joint venture, however progress on PDC/MESA's audit has been much better than anticipated and the parties have determined that purchasing MESA would be better for all of the parties and their respective  shareholders .

MESA focuses on providing custom compounded non-narcotic, transdermal topical pain medications that are marketed to industrial health physicians and clinics. MESA has developed a series of topical ointments, in different strengths, that provide the pain relief doctors seek.

During the current month, according to MESA, it has received more than  $3,400,000 in orders and filled more than  $1,500,000 in actual prescriptions. MESA believes that it is on track to exceed  $25,000,000 in revenues during  fiscal year 2014 with much greater revenues a very real possibility.

PDC will be paid a royalty on collection for each prescription filled by MESA as well as receiving 500,000 shares of PAWS Series D Convertible Preferred Stock. The parties will begin the process of transferring MESA's license from PDC to PAWS as soon as possible and the  transaction is intended to close upon the issuance of a new  California pharmacy license or sooner. PDC has the right to appoint three members to the Board of Directors as soon as the new license is issued and the audit of MESA's operations is completed.

Furthermore, the holders of a majority of the Company's Series B Convertible  Preferred Stock shares have agreed to vote to reduce the maximum conversion rate in order to offset the new Series D stock, on a fully diluted basis.

Additionally, PAWS intends to spin off its remaining airline related properties, freeing the Company of much of its debt and further intends to settle most of its remaining debt in the very near future.

"We are excited about these developments, for our company and our shareholders, and we believe with MESA's great team, a great  foundation for future growth is set", said Dan Wiesel CEO of The PAWS Pet Company. He continued, "With the execution of this agreement, the way forward for PAWS is clear and we will now focus on completing the licensing process, domesticating the Company in  Nevada and changing our name to Praxsyn Corporation."

About The PAWS Pet Company, Inc.

The PAWS Pet Company, Inc. is undergoing a transition from the pet space to the pharmaceutical space. This exciting transition strategy has been developed to take advantage of the changes underway in traditional medical services. PAWS believes that great  opportunities exist in pharmaceuticals and how they are delivered to the public.

For more information on The PAWS Pet Company go to www.thepawspetcompany.com
For more  information on Pharmacy Development Inc. go to www.pharmacydevelopment.com
Company Contact: ir@thepawspetcompany.com

Forward-Looking Statements

Certain statements made in this press release are forward-looking in nature (within the meaning of the Private Securities Litigation Reform Act of 1995) and, accordingly, are subject to risks and uncertainties. The actual results may differ materially from those described or contemplated and consequently, you should not rely on these forward-looking statements as predictions of future events. Certain of these risks and uncertainties are discussed in the reports we filed with the SEC.

SOURCE The PAWS Pet Company, Inc.

Copyright 2013 PR Newswire

My Favorite plays are on the Nasdaq DIP and RIP Board http://investorshangout.com/NASDAQ-DIP-and-RIP-87909/
My Favorite Paid chat room with amazing chart setups is The Trading Stock Lounge http://www.thetradingstocklounge.com/

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Roborock Fuels Market Surge with 27.6% Revenue Boost

Updated Category News Views 1

Roborock's Rocket-Like Ascent in Global Markets Call me impressed, but Roborock is really hitting its stride. The company's been on a tear, pulling in RMB 10.084 billion during the first half of 2026—a remarkable 27.6% bump from last year. Not just content with the revenue surge, they also saw net profits jump 45.6%, making it pretty clear that they're not just playing...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
DUVA ONE Sleep Earbuds: Real-Time Innovation Debuts

Updated Category News Views 3

While You Dream, DUVA ONE Works Here's the scoop: DUVA just took sleep tech to another level with their DUVA ONE earbuds launched at Berlin's IFA 2026. These aren't just any earbuds; they're engineered to actually do something while you're sleeping. DUVA ONE senses what’s happening during your snooze session and adjusts right on the fly. The Night Patrol: In-Ear and...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
See's Candies Data Breach Spurs Legal Scrutiny

Updated Category News Views 12

Data Breach Hits See's Candies Hard Amidst Ransomware Attack Alright, folks, here's a not-so-sweet tale to kick off your day — See's Candies has found itself in a bit of a pickle. A ransomware attack, the nasty kind that makes you double-check your locks and your passwords, has reportedly exposed the personal data of its customers and employees. We're talking names,...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 7

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Changhong's IFA 2026 Showcase: AI, Culture & Localization

Updated Category News Views 3

Changhong's Game Plan: From Global Reach to Local Touch Well, Changhong's not sitting back at IFA 2026, let me tell you that. This isn't your run-of-the-mill showcase; it's a full-on reveal of what happens when a company takes AI tech and tunes it to the heartbeat of daily life. TVs, fridges, air conditioners—you name it, they've got an AI twist on it. But is this just...

Continue Reading

Top 5 Most Recently Viewed Articles

Discover Space-ng's New Computer Vision Solutions

Updated Category News Views 125

Introducing Space-ng's Innovative Vision System Space-ng is excited to present a revolutionary Hardware Development Kit (HDK) and a Software Development Kit (SDK) tailored for their renowned Sol3 Vision System. This initiative embodies a commitment to affordable, rugged, and air-cooled technology suitable for space applications. The HDK is designed for rapid prototyping,...

Continue Reading
iOnctura Advances Treatment Options for Uveal Melanoma Patients

Updated Category News Views 182

iOnctura Reports Significant Clinical Progress in Uveal Melanoma iOnctura, a clinical-stage biopharmaceutical company, has recently unveiled critical advancements in its efforts to combat uveal melanoma, a rare form of eye cancer that often presents significant treatment challenges. The company has completed its Phase I DIONE-01 study, showcasing encouraging clinical...

Continue Reading
Spyre Therapeutics Progresses with SPY001 for IBD Treatment

Updated Category News Views 115

Spyre Therapeutics Reports Encouraging Phase 1 Trial Data Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company, has recently released promising interim results from its Phase 1 trial of SPY001, an innovative half-life extended monoclonal antibody aimed at treating inflammatory bowel disease (IBD). The study indicates that SPY001 was well...

Continue Reading
Understanding the University of Phoenix Tuition Guarantee

Updated Category News Views 194

Understanding the University of Phoenix Tuition Guarantee Fixed tuition and new transparency initiatives support adult learners in planning educational expenses. University of Phoenix is enhancing its commitment to clear and consistent tuition costs through its Tuition Guarantee initiative. This program ensures that students benefit from a locked-in tuition rate from the...

Continue Reading
Halper Sadeh Investigates Shareholder Rights for IPXX, PWUP, DECA, TTNP

Updated Category News Views 38

Halper Sadeh LLC Investigates Shareholder Rights Halper Sadeh LLC, a law firm dedicated to protecting investor rights, is currently examining several companies for potential violations of federal securities laws and breaches of fiduciary duties. This investigation focuses on significant firms involved in mergers, with the aim of safeguarding shareholder interests....

Continue Reading